Heparin Axicur (Heparin Sodium)

Heparin Axicur is indicated for clinical situations where anticoagulation is required to reduce the risk of clot formation.

• Prevention and treatment of arterial or venous thrombosis.
• Prophylaxis of venous thromboembolism (VTE) in patients undergoing surgery or immobilization.
• Management of deep vein thrombosis (DVT) and pulmonary embolism (PE) as part of a broader therapeutic regimen.
• Use in patients at risk of clot propagation during acute coronary syndromes when administered under medical supervision.

Heparin Axicur may be associated with a range of adverse reactions, most of which are related to its anticoagulant activity.

Common

• Local skin reactions such as erythema, itching, or mild bruising at the application site.
• Minor bleeding episodes, including nosebleeds or gum bleeding.
• Transient elevation of liver enzymes in some patients.

Serious

• Severe hemorrhage, including gastrointestinal or intracranial bleeding.
• Heparin-induced thrombocytopenia (HIT), an immune-mediated drop in platelet count.
• Allergic reactions ranging from urticaria to anaphylaxis.

Before using Heparin Axicur, healthcare professionals should evaluate patient-specific factors and monitor for potential complications.

• Assess bleeding risk, including recent surgery, trauma, or active gastrointestinal ulcers.
• Review patient history for heparin-induced thrombocytopenia or known hypersensitivity to heparin.
• Monitor platelet counts regularly during prolonged therapy to detect HIT early.
• Adjust dose or discontinue if uncontrolled bleeding or significant drop in hemoglobin occurs.
• Use caution in pregnant or lactating individuals; benefits and risks should be weighed by a clinician.
• Evaluate renal and hepatic function, as impairment may affect drug metabolism and safety.

Heparin Axicur can interact with other medications that affect coagulation or platelet function.

Avoid

• Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) unless specifically directed.
• Combination with antiplatelet agents such as aspirin, clopidogrel, or NSAIDs that increase bleeding risk.
• Simultaneous administration of thrombolytic agents (e.g., alteplase, streptokinase).

Use with caution

• Concomitant use of non‑steroidal anti‑inflammatory drugs (NSAIDs) may modestly increase bleeding tendency.
• Co‑administration with drugs that affect platelet function (e.g., selective serotonin reuptake inhibitors) should be monitored.
• Use with corticosteroids may exacerbate skin irritation at the application site.